bone metastasis Clinical Trials

7 recruitingLast updated: May 11, 2026

There are 7 actively recruiting bone metastasis clinical trials across 5 countries. Studies span Not Applicable, Phase 2. Top locations include Boston, Massachusetts, United States, Brest, Brest, France, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


bone metastasis Trials at a Glance

7 actively recruiting trials for bone metastasis are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Boston, Brest, and Houston. Lead sponsors running bone metastasis studies include Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and Ebrahim S Delpassand.

Browse bone metastasis trials by phase

About bone metastasis Clinical Trials

Looking for clinical trials for bone metastasis? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new bone metastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about bone metastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

bone metastasisPSMA PETProstate Cancer (Diagnosis)+4 more
Xijing Hospital1,000 enrolled9 locationsNCT07553754
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+15 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Not Applicable

Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality

bone metastasisOncology Pain
Institut de Cancérologie de Lorraine598 enrolled4 locationsNCT06884332
Recruiting

FDG PET-CT in Advanced Breast Cancer

Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment AvailableIf There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
Samsung Medical Center100 enrolled1 locationNCT07173868
Recruiting

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano500 enrolled1 locationNCT07030569
Recruiting
Phase 2

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Prostate CancerProstate Cancer MetastaticMetastatic Castration-resistant Prostate Cancer+2 more
Ebrahim S Delpassand30 enrolled1 locationNCT06972628
Recruiting
Not Applicable

Biomolecular Markers of Bone Metastasis

bone metastasis
IRCCS Azienda Ospedaliero-Universitaria di Bologna160 enrolled1 locationNCT06806462